Lanograv. Telatri 144.5 mg FC tablet.
PDF Leaflet Revision Date: 06 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults aged 18 years and older.
Dosage (summary)
One tablet orally once daily, without regard to food.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use during pregnancy may increase risk of neural tube defects; not recommended for breastfeeding.
Key Drug Interactions
- Rifampicin decreases dolutegravir levels
- Metformin contraindicated
Contraindications
- Hypersensitivity to components
- Renal impairment
- Concomitant use with adefovir dipivoxil
- Moderate and severe hepatic impairment
Common side effects
- Nausea
- Diarrhoea
- Fatigue
- Rash
- Headache
Counselling Points
- Monitor for signs of lactic acidosis
- Avoid breastfeeding
- Use effective contraception in women of childbearing potential
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Risk of opportunistic infections
Important Disclaimer
The Lanograv. Telatri 144.5 mg FC tablet. professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
